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Abstract
Numerous constraints significantly hamper the experimental study of hepatitis C virus (HCV). Robust replication in cell
culture occurs with only a few strains, and is invariably accompanied by adaptive mutations that impair in vivo infectivity/
replication. This problem complicates the production and study of authentic HCV, including the most prevalent and
clinically important genotype 1 (subtypes 1a and 1b). Here we describe a novel cell culture approach to generate infectious
HCV virions without the HCV replication requirement and the associated cell-adaptive mutations. The system is based on
our finding that the intracellular environment generated by a West-Nile virus (WNV) subgenomic replicon rendered a
mammalian cell line permissive for assembly and release of infectious HCV particles, wherein the HCV RNA with correct 59
and 39 termini was produced in the cytoplasm by a plasmid-driven dual bacteriophage RNA polymerase-based
transcription/amplification system. The released particles preferentially contained the HCV-based RNA compared to the
WNV subgenomic RNA. Several variations of this system are described with different HCV-based RNAs: (i) HCV bicistronic
particles (HCVbp) containing RNA encoding the HCV structural genes upstream of a cell-adapted subgenomic replicon, (ii)
HCV reporter particles (HCVrp) containing RNA encoding the bacteriophage SP6 RNA polymerase in place of HCV
nonstructural genes, and (iii) HCV wild-type particles (HCVwt) containing unmodified RNA genomes of diverse genotypes
(1a, strain H77; 1b, strain Con1; 2a, strain JFH-1). Infectivity was assessed based on the signals generated by the HCV RNA
molecules introduced into the cytoplasm of target cells upon virus entry, i.e. HCV RNA replication and protein production
for HCVbp in Huh-7.5 cells as well as for HCVwt in HepG2-CD81 cells and human liver slices, and SP6 RNA polymerase-driven
firefly luciferase for HCVrp in target cells displaying candidate HCV surface receptors. HCV infectivity was inhibited by pre-
incubation of the particles with anti-HCV antibodies and by a treatment of the target cells with leukocyte interferon plus
ribavirin. The production of authentic infectious HCV particles of virtually any genotype without the adaptive mutations
associated with in vitro HCV replication represents a new paradigm to decipher the requirements for HCV assembly, release,
and entry, amenable to analyses of wild type and genetically modified viruses of the most clinically significant HCV
genotypes.
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Introduction
HCV infects 2–3% of the world population. A majority of
infected people fail to clear the virus and are at risk for developing
serious liver complications (reviewed in [1]). HCV belongs to the
genus Hepacivirus in the Flaviviridæ family, and at least six genotypes
have been identified so far [2]. Greater than two thirds of HCV
infections diagnosed worldwide are of subtypes 1a or 1b [2]. There
is no approved vaccine and available treatments are much less
effective against genotype 1 compared to other genotypes. The
limited experimental availability of chimpanzees, the primary
animal model for HCV [3,4], and difficulties encountered in
reproducing true infection in small animals have significantly
limited the use of in vivo models to study the biology of this virus.
The structure of the intact virion is unknown, and it is still unclear
how the RNA genome [5] circulates in infected patients. In
addition, although the natural target cells of HCV are primarily
hepatocytes in the liver, in vitro most human hepatic cells poorly
propagate HCV isolates from patients (e.g. [6]). In vitro studies
were nevertheless marked by two breakthroughs allowing for the
screening of new antiviral compounds. First, subgenomic replicons
(i.e. without structural genes) of subtypes 1b [7,8] and 1a [9] were
established in selected subclones of the human hepatic Huh-7 cell
line that are highly permissive for HCV replication, e.g. Huh-7.5
cells [10]. Subsequently, a full infectious cycle was reproduced in
cell culture with JFH-1, a particular strain of genotype 2a [11,12],
or with a J6/JFH-1 chimera [13]; the released particles are
referred to as HCVcc.
Although propagation of a few HCV strains in replication-
permissive cell lines has been an important contribution to the
field, it has long been recognized that these models are
complicated by the particularly high error rate of the HCV
PLoS Pathogens | www.plospathogens.org 1 April 2011 | Volume 7 | Issue 4 | e1001333RNA replicase [14]. Combined with the in vitro selective pressure,
e.g. associated with the modifications acquired by the permissive
cell lines [15], or viral recombination between genotypes [16–18],
it inevitably results in the emergence of adaptive/escape variants
[19]. However, cell culture-adapted HCV most often displays lack
of infectivity or impaired fitness in vivo [20,21]. Conversely, HCV
genomes with a consensus sequence that are infectious in
chimpanzees are not infectious in cell culture, e.g. in Huh-7.5
cells [9,22]. This issue is especially perplexing with genotype 1
strains, for which the accumulation of cell-adaptive mutations that
enhance its RNA replication results at best in low yields of HCVcc
with impaired infectivity [19,23]. Intergenotypic JFH-1 chimeras
have been engineered to tentatively overcome such limitations
[16–18] but have been shown to accumulate structural gene
compensatory mutations [16]. As such mutations and their
associated complications result from the viral RNA replication
process, we reasoned that uncoupling the production of infectious
HCV particles from HCV RNA replication would circumvent
major limitations associated with existing in vitro systems requiring
such coupling.
All known Flaviviridæ members replicate in the cytoplasm of their
target cells and induce membrane rearrangements mostly deriving
from the endoplasmic reticulum (ER) [24,25]. Strongly connected
to RNA replication [26], assembly of infectious flavivirus particles
occurs within a distinct sub-compartment of rearranged mem-
branes [27,28]. It has been possible to produce flavivirus virions by
providing their structural genes in trans. Thus, upon expression of
WNV structural genes: core, pre-membrane (prM) and envelope
(E), baby hamster kidney (BHK)-21 cells carrying a WNV
subgenomic replicon encoding a reporter gene release infectious
WNV reporter-particles (WNVrp) containing subgenomic replicon
RNA [29,30]. Although distantly related within the Flaviviridæ
family, the Flavivirus and Hepacivirus genera display common features
[31]. We therefore examined whether, as for WNV, infectious
HCV particles could be formed when the structural proteins are
encoded in trans. While we did not observe such trans-comple-
mentation in a HCV replication-permissive cell line, we made the
surprising observation that non-hepatic mammalian cells previ-
ously used to study the biology of Flaviviridæ (including HCV) and
bearing a flavivirus subgenomic replicon can produce infectious
HCV of diverse genotypes from genomic RNA produced by a
plasmid-based system involving cytoplasmic transcription by
bacteriophage T7 RNA polymerase. The lack of involvement of
the HCV RNA replication machinery avoids the occurrence of
cell-adaptive mutations in the HCV genomes.
Results
Assembly and release of HCV particles by BHK-WNV cells
In initial analyses of the possible effects of flavivirus replicons on
HCV virus particle production from proteins provided in trans,w e
observed that release of HCV structural proteins (expressed from a
cytomegalovirus immediate early promoter and harvested by
ultracentrifugation) was dramatically enhanced in BHK-21 cells
carrying a lineage II WNV subgenomic replicon [32] (referred to
as BHK-WNV cells in this study) compared to parental cells; a less
pronounced increase was observed in the cell lysate (Fig. 1A). This
result suggests that, in the complete absence of HCV RNA
replication, the WNV subgenomic replicon had generated a
permissive environment for releasing HCV particles. Surprisingly,
these effects were not observed in the seemingly more relevant
Huh-7.5 human hepatocyte cell line, in which we found that the
presence of an HCV subgenomic replicon inhibited rather than
stimulated release of HCV structural proteins (both of genotype
1a) provided in trans (Fig. S1A). Moreover, we were unable to
stably establish an HCV subgenomic replicon in BHK-21 cells.
Based on these results, we considered the potential of the BHK-
WNV cell system to produce infectious HCV particles if
appropriate HCV-based RNA molecules were generated in the
cytoplasm. Such a system might potentially enable virus
production of the most prevalent but experimentally difficult
genotype 1 strains.
Model system for production of infectious HCV particles
in BHK-WNV cells
To test this hypothesis, we devised a strategy for generating
HCV-based RNA molecules in the cytoplasm of BHK-WNV cells
(Fig. 1B). One component of this approach consisted of a dual-
plasmid bacteriophage polymerase (p2B) system consisting of the
genes for the DNA-dependent RNA polymerases from both
bacteriophages T7 and SP6 (T7pol and SP6pol, respectively), each
linked to their reciprocal promoter. The other component was a
plasmid encoding the HCV genomic sequence of interest flanked
at the 59 end by the bacteriophage T7 promoter, and at the 39 end
by a hepatitis delta virus antisense ribozyme (HDVrbz; cf. Materials
and Methods). We reasoned that co-transfection of these two
components into BHK-WNV cells would result in cytoplasmic co-
amplification of both bacteriophage polymerases; T7 Pol would
then drive high level cytoplasmic production of uncapped HCV
genomic RNA with correct 39 termini (by HDV rbz self-cleavage)
that would serve as template for translation of HCV proteins
(driven by the HCV IRES), including the structural proteins core,
E1 and E2. Assembly and release of particles composed of HCV
structural proteins and containing the HCV-based RNA might
then occur (Fig. 1C), and such particles might be infectious for
appropriate target cells.
Production of HCV bicistronic particles in BHK-WNV cells
We first generated HCV bicistronic particles (HCVbp) using a
plasmid encoding HCV 59-UTR to NS2 sequence upstream of the
encephalomyocarditis virus (EMCV) IRES of a Huh-7.5 cell-
adapted HCV subgenomic replicon of subtype 1a [9], thereby
Author Summary
Two decades after its identification, hepatitis C virus (HCV)
remains a leading cause of serious liver diseases world-
wide. The poor in vitro propagation of patient isolates has
impaired their study. Conversely, viral strains of the most
prevalent (,70% of total infections) and clinically prob-
lematic (,45% cured with the standard of care) genotype
1 adapted for in vitro replication display mutations
impairing yield and/or in vivo infectivity. We established
a new cell culture model for producing infectious HCV in a
cell line stably bearing a subgenomic replicon from West
Nile virus (a flavivirus belonging to the same family as HCV)
that circumvents the requirement for HCV RNA replication.
To study viral infectivity in vitro, we devised several HCV
genome-based constructs. This system produced wild type
HCV particles of subtypes 1a, 1b, 2a and a 1b/2a chimera.
All specifically infected permissive target cells, and HCV
particles containing wild type genomes known to be
infectious in vivo infected human liver slices ex vivo. The
production of authentic HCV particles independent of HCV
RNA replication represents a new paradigm to decipher
requirements for HCV assembly, release, and entry,
amenable to analyses of wild type and genetically
modified viruses of the most clinically significant geno-
types.
Production of HCV without Involving Replication
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Huh-7.5 cells. Co-transfection of BHK-WNV cells with this
plasmid plus the p2B system resulted in the formation of large
vesicles (not classical multi-vesicular bodies) filled with 50–60-nm
particles in the vicinity of dilated rough ER protrusions and
mitochondria, as observed by transmission electron microscopy
(Fig. 2B, top panels). In contrast, BHK-WNV cells transfected with
a control plasmid (HCV subgenomic replicon minus the HCV
structural genes) displayed the extensive membrane rearrange-
ments previously shown to be triggered by the WNV subgenomic
replicon [25] (Fig. 2B, lower left panel), such as vesicle packets (site
of WNV RNA replication) and convoluted membranes (site of
WNV RNA translation and polyprotein processing); however the
large vesicles containing particles were not observed (Fig. 2B,
lower right panel). Immuno-gold electron microscopy analysis with
anti-HCV E1 and anti-core antibodies revealed the presence of
the corresponding HCV proteins within membrane rearrange-
ments or large vesicles (Fig. S2) in BHK-WNV cells expressing the
bicistronic HCV full length construct.
Fig. 3A shows quantitation of viral RNA (WNV and HCV) in
BHK-WNV cells and the corresponding culture supernatants (SN)
after their ultracentrifugation. As expected, the cells contained a
large amount of WNV RNA generated by the WNV subgenomic
replicon, independent of transfection with the HCVbp-encoding
plasmid. In contrast, HCV RNA was observed only in cells
expressing this plasmid, at levels comparable to the WNV RNA.
Strikingly, this was accompanied by the appearance in the SN of a
large amount of HCV RNA, which was highly enriched
(approximately 100-fold) relative to the WNV RNA. Sucrose
density gradient analysis of particulate material from the culture
supernatant indicated that the HCV-based RNA migrated over a
broad buoyant density range of 1.05 to 1.20 g/cm
3 (Fig. 3B). The
HCV E1 glycoprotein was detected across the gradient, as were
the other structural proteins core and E2 (Fig. S3A, upper panels).
These results suggest that the BHK-WNV cell system is capable of
releasing particles composed of HCV structural proteins that are
preferentially associated with the HCV-based RNA from which
they were translated.
We determined that the harvested particles were not exosomes
or cell debris, consistent with a requirement for maturation of
HCV envelope proteins for particle release in our system (Text S1
and Fig S3A–C). We also excluded that the WNV RNA released
upon transfection of the HCVbp plasmid in BHK-WNV cells
(Fig. 3A) was associated with infectious particles. First, previous
reports suggest a requirement for WNV core protein [26]. In
addition, after the transfection of BHK-WNV cells with a plasmid
encoding WNV structural proteins, the secreted particles (WNVrp)
were infectious for Huh-7.5 cells (Fig. S3D), consistent with
previous findings using other target cells [32]. However,
incubation of Huh-7.5 cells with HCVbp did not yield any Renilla
luciferase activity. Finally, BHK-WNV cells were treated with
antiviral drugs for two weeks, which inhibited the WNV replicon
(measured by the reduced expression of Renilla luciferase) but did
not affect the release of HCV particles (Fig. S3E). It is therefore
highly unlikely that HCV RNA replication is responsible for the
production of HCV in this system (data on the mechanism will be
presented elsewhere).
Infectivity of HCVbp for Huh-7.5 cells
Several criteria were examined to test the infectivity of the
HCVbp in Huh-7.5 cells. First, we used RT-qPCR for the 59-
UTR to test individual fractions from the sucrose density gradient
in Fig. 3B for their ability to induce HCV RNA replication. As
shown in Fig. 4A, the amounts of HCV RNA in target cells at day
3 post-infection were negligible for nearly all fractions, and
increased substantially by day 4. As previously reported for
HCVcc [23,33], we observed that the infectivity of HCVbp was
spread over a broad range of buoyant densities, and that it did not
directly correlate with the detected amounts of viral RNA. The
peak of infectivity generally ranged between 1.08–1.13 g/cm
3
(Fig. 4A), which corresponded to a low peak of HCV RNA
(Fig. 3B). Infectious titers of HCVbp in the supernatants of BHK-
WNV cells were measured in Huh-7.5 cells. TCID50 were between
0.6610
4 units/ml at day 3 and 2.5610
5 units/ml at day 4 (cf. Text
S1), consistent with data presented in Fig. 4A. Such viral titers are
about one log lower than with the JFH-1 strain [11,12] and
genotype 2a chimera [13] after a two-day incubation in permissive
cell lines, but at least 10-fold higher than with HCVcc obtained
with a cell culture-adapted strain of genotype 1 [23].
The relatively low buoyant density of most infectious particles
could relate to their association with lipids, since lipid droplets
were detected in the vicinity of non-structural proteins in BHK-
WNV cells expressing the HCVbp-4cys construct, encoding a
tetracysteine tag within NS5A (Fig. S4A). As BHK-21 cells express
functional LDL receptor [34], another non-exclusive possibility is
that HCV particles interacted with lipoproteins from the culture
medium. Incubating HCVbp with (up to 0.15 mg/ml) human
VLDL, LDL or HDL in vitro prior to Huh-7.5 cells enhanced the
amount of viral RNA accumulating in target cells up to 5-fold (not
shown), which would be consistent with a specific interaction of
lipoproteins with pre-assembled HCVbp, as previously reported
for HCV-like particles (HCV-LPs) [35], lentiviral particles pseudo-
typed with HCV envelope proteins (HCVpp) and HCVcc [36].
We also analyzed HCVbp-induced synthesis of HCV proteins
and RNA in Huh-7.5 target cells by laser-scanning confocal
microscopy. Based on staining with a polyclonal antibody against
NS5A (Fig. 4B; specificity of antibody validated in Fig. S4C),
NS5A-positive patches were detected in the cytoplasm of Huh-7.5
cells infected with HCVbp for two days (center and right panels),
but not in uninfected cells (left panel). Albeit in close proximity
with ERGIC53, these patches did not co-localize with this lectin
that transports glycoproteins from the ER to the Golgi apparatus,
suggesting that NS5A was not associated with a ‘classic’ membrane
compartment. We also examined HCV RNA replication in Huh-
Figure 1. WNV subgenomic replicon enhances the release of HCV particles. (A) HCV structural genes (core to p7, driven by a CMV promoter)
were expressed in BHK-21 or BHK-WNV cells. Three days later, equal amounts of lysates (cells) and SN (corresponding to pellets from 15 ml culture
media ultracentrifuged through 15% sucrose cushion) from both cell types were loaded onto a gel, and HCV proteins (E2, E1 and core) were analyzed
by Western blot. (B) System of plasmids to produce HCV particles in BHK-WNV cells: the plasmid-driven dual bacteriophage RNA polymerase-based
transcription/amplification (p2B) system consists of two plasmids (cf. Materials and Methods) producing T7 and Sp6 bacteriophage DNA-dependent
RNA polymerases (DdRp) that cross-amplify each other’s transcription and were used to generate uncapped RNA with T7 promoter-driven HCV-
encoding plasmids in the cytoplasm of producer cells. HDV rbz=hepatitis delta virus antisense ribozyme; T7 Pol=T7 DdRp; T7pol (or SP6pol)=T7 (or
SP6) DdRp genes; T7p (or SP6p)=T7 (or SP6 Pol) cognate promoter. (C) Cartoon depicting the main components involved in the system to produce
infectious HCV particle by BHK-WNV cells: left (orange), the intracytoplasmic production of T7 Pol-transcribed HCV genomic RNA; right (blue), cellular
changes induced by the stably established WNV subgenomic replicon, including intracytoplasmic membrane rearrangements; bottom (green), HCV
assembly and release.
doi:10.1371/journal.ppat.1001333.g001
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treated with actinomycin D to block RNA polymerase II-
dependent nuclear transcription, then loaded with 5-bromo-
UTP, a nucleotide analog that is incorporated into elongating
RNA. Staining of HCVbp-infected cells with anti-bromo-uridine
(BrU) and NS5A antibodies resulted in the detection of both
signals in a cytoplasmic subcompartment of Huh-7.5 cells
incubated with HCVbp (Fig. 4C, center panels). This staining
pattern was very similar to that observed in positive control cells,
i.e. Huh-7.5 cells bearing an HCV subgenomic replicon (Fig. 4C,
right panels), but not observed in the uninfected negative control
cells (Fig. 4C, left panels). This result presumably reflects the local
incorporation of BrU into replicating HCV-based RNA, as has
been shown for flaviviruses [37]. Consistent results were obtained
with live cells infected with particles encoding a tetra-cysteine tag
in NS5A (Fig. S4D).
Treatment of cells with viral inhibitors (interferon a or b plus
ribavirin) prior to their inoculation with HCVbp inhibited the
accumulation of viral RNA by ,10-fold (not shown). The
sensitivity of HCV replication to these agents [38] suggests that
HCVbp-mediated increase in HCV RNA reflects the activity of
the introduced subgenomic replicon. The pre-incubation of
HCVbp with serum from an HCV-cured patient (without
circulating HCV RNA by PCR) decreased the amount of
intracellular RNA (Fig. S4B) detected by RT-qPCR, compared
to that with normal/naive human serum, suggesting the existence
of a specific interaction of HCVbp with the immune serum
(presumably IgG) interfering with their infectivity.
Receptors involved in HCVbp entry
The CD81 tetraspanin has been implicated as an important
receptor for HCV entry [39]. Albeit of human hepatic origin, the
HepG2 cell line lacks CD81 and is poorly permissive for HCV
entry but can be rendered permissive by CD81 expression, as
previously shown by infection with HCVpp [40] or HCVcc [41].
We found that stable transduction of these cells with a
recombinant lentivirus encoding human CD81 resulted in its
surface expression (Fig. S5A); it enhanced the NS5A signal
triggered by the incubation of HepG2 cells with HCVbp (Fig. 5A;
compare right and left panels).
For more quantitative analyses, we devised a variation of the
system involving the production of HCV reporter particles
(HCVrp). To this end, the fragment encoding NS3 up to the last
third of HCV NS5B in the HCVbp construct was replaced with
one encoding the ORF of bacteriophage SP6 RNA polymerase
(SP6 Pol; Fig. 5B, top). After HCVrp entry into target cells, these
cells were co-transfected with the p2B system plus a plasmid
encoding EGFP fused with Firefly luciferase, linked to the T7 and
SP6 promoters and an EMCV IRES (Fig. 5B, bottom), and were
treated with actinomycin D to decrease the background reporter
gene expression in the absence of incoming SP6 Pol-encoding
RNA, which triggers reporter gene expression in a dose-dependent
manner, independent of most post-entry processes. As predicted,
parental BHK failed to release infectious HCVrp (Fig. S5B).
Although EGFP expression was also observed, only luciferase
activity is reported. We tested the dependence of HCVrp entry (cf.
Text S1 and Table S1) on surface molecules previously implicated
as essential entry receptors in target cells (Fig. 5C). Inhibition of
the Firefly luciferase signal generated by HCVrp entry occurred
when Huh-7.5 cells were pretreated with siRNA pools targeting
several HCV candidate receptor molecules: SR-B1 [42], CD81
[39], ASGP-R subunits 1 and 2 [43], and to a lesser extent
claudin-1 [44] (Fig. 5C, filled bars). The same siRNA treatments
had little effect on entry of WNVrp (generated by transfecting
BHK-WNV cells with a plasmid encoding WNV structural
proteins), as measured by the Renilla luciferase activities encoded
by the WNV subgenomic replicon packaged into WNVrp (Fig. 5C,
open bars). SR-B1 siRNA was the most effective at blocking both
the protein expression (Fig. S5C) and HCVrp entry (Fig. 5C).
Consistently, pre-incubation of Huh-7.5 cells with antibodies
against CD81 and SR-B1 significantly inhibited HCVrp entry
signal (Fig. S5D). The interaction of HCV E2 hypervariable
region 1 (HVR-1) interaction with SR-B1 is critical for infection
[42] and in vivo infection has previously been neutralized by an
antiserum against HVR-1 [45]. Preliminary data (reagent was
made available in very limited quantity) shows that incubation of
HCVrp with these anti-HVR-1 antibodies also inhibited their
entry into Huh-7.5 cells (Fig. S5E).
Production of JFH-1 strain-based HCV by BHK-WNV cells
We also tested the possibility of producing infectious particles
based on the ability of the JFH-1 strain to infect Huh-7.5 cells
[11]. Plasmids encoding the genomic RNA of JFH-1 [11] or a
Con1-JFH1 (1b-2a) chimera [18] under a T7 promoter were
transfected into BHK-WNV producer cells and HCV particles
were harvested, then incubated with Huh-7.5 cells. Fig. 6A–B
shows the detection of viral RNA in the target cells for both
constructs. Starting at day 3, increasing RNA amounts were
measured, whereas in cells treated with interferon plus ribavirin no
such increase was detected (Fig. 6A–B).
BHK-WNV cells produce authentic infectious HCV
As an additional variation of this HCV expression approach, we
tested the possibility that BHK-WNV cells could produce
authentic infectious HCV particles. We co-transfected BHK-
WNV cells with the p2B system and a plasmid encoding a full-
length genomic RNA with the consensus sequence of a strain of
genotype 1a (H77, Fig. 7A), which has been shown to be infectious
in chimpanzees [46]. The ‘wild type’ particles (HCVwt) released
into the supernatants were harvested by ultracentrifugation and
analyzed by sucrose density gradient centrifugation. In fractions
with buoyant densities of 1.08–1.13 g/cm
3, spherical particles of
50–60 nm in diameter were observed by negative staining electron
microscopy; these were not observed with corresponding fractions
from control BHK-WNV cells. Some of these particles were
positive by immuno-gold electron microscopy, indicating their
recognition by immunoglobulins from an HCV-cured patient
(Fig. 7B).
Figure 2. BHK-WNV cells assemble HCV bicistronic particles. (A) p684-SG(L+I)-HDV (top) is derived from pH-Neo-SG(L+I) plasmid (bottom), in
which NeoR gene was replaced with HCV 59-UTR to NS2 genes; a HDVrbz gene was introduced at the 39 end of the HCV RNA of both constructs. It
encodes a bicistronic full length HCV genome with cell-culture adaptive mutations (*). (B) BHK-WNV cells were transfected with the p2B system plus
p684-SG(L+I)-HDV (top panels), or pH-Neo-SG(L+I)-HDV (bottom panels), and three days later subjected to TEM analyses: (Top panels) large vesicles
(LV) filled with virus-like structures appeared (black arrow) next to dilated rough ER protrusions. At higher magnification: electron-dense, spherical,
enveloped particles are budding into the lumen of LV (arrows). (Lower panels) BHK-WNV cells displayed extensive intracellular membrane
rearrangements with numerous intracytoplasmic vesicles most likely representing the convoluted membranes (CM) and vesicle packets (VP) induced
by WNV subgenomic replicon; these features are absent from parental cells (not shown). At higher magnification, these vesicles are mostly empty or
contained non-specific cellular materials. Scale bars: left panels=500 mm; right panels=100 mm; inset,=50 nm.
doi:10.1371/journal.ppat.1001333.g002
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PLoS Pathogens | www.plospathogens.org 6 April 2011 | Volume 7 | Issue 4 | e1001333Figure 3. HCV RNA is preferentially associated with in HCV bicistronic particles released by BHK-WNV cells. (A) Three days after transfection of
BHK-WNV cells with HCVbp-coding plasmid, RNA was extracted from cells and pellets of supernatants ultracentrifuged through sucrose cushion (SN); WNV and
HCV RNA were each quantified by RT-qPCR; a similar protocol was used for control (untransfected) cells. The values on the Y-axis represent the amounts of cell-
and SN-associated RNA extracted from an equivalent number of cells. (B) HCVbp released by BHK-WNV cells were analyzed on a 20–60% sucrose gradient; HCV
E1 was detected by Western blot (top panel) and HCV RNA 59-UTR measured by RT-Taqman PCR (bottom panel).
doi:10.1371/journal.ppat.1001333.g003
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PLoS Pathogens | www.plospathogens.org 8 April 2011 | Volume 7 | Issue 4 | e1001333As HCV isolates from patients are poorly infectious in Huh-7
cells [6], the infectivity of HCVwt was tested in liver slices from
non-infected patients (negative for HCV, HBV and HIV). Like
primary human hepatocytes [47], liver slices can be infected ex vivo
with HCVcc (unpublished). The liver slices presumably better
reflect the real situation than cell lines do, as both the architecture
and cell type diversity of the liver are maintained in their original
configuration. After incubation of liver slices with BHK-WNV
cell-produced HCVwt (H77 strain) [46] or Huh-7.5 cell-produced
HCVcc (JFH-1 strain) [11], specific staining by anti-HCV
antibodies was analyzed by multifocal confocal microscopy; after
a few days, the signal appeared within the slices at various
locations of a few lobules, and increased up to 6–10 days. Fig. 7C
(upper panels) shows data obtained at day 8; positive staining by
both serum from HCV-infected and monoclonal antibodies
against structural proteins was observed (middle panel) within
two to five lobules of HCVwt-infected slices (area .1c m
2). The
results were similar to those obtained after infection with HCVcc
(right panel), and specificity was verified by the undetectable
staining in uninfected liver slices (left panel). Infection was detected
in clusters of cells within a few lobules, consistent with a recent
report showing that HCV infection of the liver involves a limited
number of hepatocytes [48]. Results varied in shape and intensity
with liver donor, but the specificity of the detected infection signal
was further confirmed by additional analyses with control
antibodies (Fig. S6).
Similar results were obtained with HCVwt-4cys, encoding a
tetracysteine tag within its non-structural gene NS5A, as
previously validated in Huh-7.5 cells (cf. Text S1). Six to eight
days after their infection with HCVwt-4cys, liver slices were
incubated with a permeable biarsenical dye and observed with a
two-photon confocal microscope. Specific staining was detected
predominantly in a few periportal spaces, and also in mediolobular
areas (Fig. 7C, lower middle and right panels) of HCVwt-4cys-
incubated slices. In spite of a high background that reduces the
sensitivity of detection with this technology, the appearance of
small clusters of positive signals (generated in live cells) is consistent
with the local synthesis of HCV non-structural proteins in human
liver slices after their ex vivo infection with HCVwt-4cys produced
in BHK-WNV cells.
HCV produced in BHK-WNV cells infect HepG2-CD81 cells
As HCV isolates from patients are poorly replicating in Huh-7
cells [6,9,22] and access to naı ¨ve human liver slices of good quality
is limited, we tested the possibility that HCVwt could infect
HepG2-CD81 cells, which have been previously reported to
support replication of patient isolates [6]. To some extent these
cells support HCVbp replication (Fig. 5A). The incubation of
HepG2-CD81 cells with HCVwt (produced in BHK-WNV cells)
of subtypes 1a, 1b, and to a lesser extent 2a (or 1b/2a chimera; not
shown), resulted in high readings starting at day 0 (Fig. 8A–C).
Although the detected amounts of HCV RNA sharply decreased
during the first 24–48 hr, which could relate to some non-
productive binding/uptake, it raised again afterward; the later
increase was abolished by a treatment with interferon and
ribavirin added to the cells both prior to and after infection (cf.
results in Huh-7.5 cells). Incubation of HepG2-CD81 cells with
HCVwt of subtypes 1a resulted in more intracellular accumulation
of HCV RNA than what was measured after their incubation with
HCVbp of the same genotype (not shown); one possible
interpretation is that Huh-7.5 cell-adaptive mutations were
detrimental to HCVbp replication in HepG2-CD81 cells, similar
to what has previously been reported in the liver, in vivo [20].
Discussion
Producing large amounts of infectious HCV virions in cultured
cells has been difficult, especially for the most prevalent and
clinically problematic genotype 1, which in part relates to its poor
ability to replicate in vitro and the subsequent appearance of cell
culture-adaptive mutations interfering with its propagation and
infectivity. Here, we produced HCV particles of genotype 1
containing a genome previously shown to be highly infectious in
vivo [7,46]. Their ability to infect human liver slices demonstrates
the biological relevance of the particles produced in this in vitro
system. Two major features underlie independence from HCV
replication, which avoided adaptive mutations typically associated
with HCV propagation in cell culture: first, the unique and robust
strategy for producing HCV genomes in the cytoplasm indepen-
dent of HCV replication, and second, the WNV subgenomic
replicon that created an appropriate cellular environment for
HCV RNA translation as well as particle assembly and release.
HCV particle formation likely took place within membrane
rearrangements derived from those induced by the WNV
subgenomic replicon, as suggested by immuno-gold electron
microscopy results. We also observed that the release of HCV
particles by BHK cells was enhanced by lineage I WNV [49] and
serotype-2 dengue virus [50] subgenomic replicons, but not by one
of Semliki Forest virus [51], an alphavirus belonging to the
Togaviridæ family (Fig. S1B). This indicates that, beyond similarities
in genomic organizations and sequences [31], the increased
production of infectious HCV could result from common
functional properties conserved amongst members of the Flaviviridæ
family rather than strict sequence specificity of the proteins
encoded by the flavivirus subgenomic replicons. In BHK-WNV
cells, this possibility is further substantiated by the lack of
correlation between HCV production and translation of the
WNV subgenomic replicon, upon inhibition of the latter’s activity.
The replication of flaviviruses and HCV induce similar membrane
rearrangements in the cytoplasm of infected cells [24,25], and our
data confirmed that flaviviruses also infect hepatocytes [28,52]. In
Huh-7.5 cells, cholesterol metabolism has been implicated in HCV
replication [53] and lipid droplets in its assembly [54]. Likewise,
WNV replication involves cholesterol metabolism [55] and, for
dengue virus particle formation, the interaction of the viral core
with lipid droplets [56]. As the mechanisms involved in the
production of HCV by hepatocytes are still debated, these similar
features perhaps underlie part of the BHK-WNV cell permissive-
ness for HCV particle formation.
The correlation between reversal of membrane rearrangements
and loss of HCV particles production (not shown) suggests that
Figure 4. BHK-WNV cells produce HCV infectious in Huh-7.5 cells. (A) Huh-7.5 cells were incubated for 3 hr with aliquots of each fraction of
the sucrose gradient shown in Fig. 3B, then transfected with plasmid encoding core to NS2 (which enhanced the readout); cellular contents in HCV
59-UTR RNA were measured at the indicated time points by RT-TaqMan qPCR, with in vitro transcripts as standards (cf. Materials and Methods). (B)
Huh-7.5 cells were incubated with HCVbp produced and harvested as described in Materials and Methods and, two days later, analyzed by confocal
microscopy; NS5A was stained (red) with in-house rabbit polyclonal IgG; cells were counterstained with ERGIC-53 (green) and DAPI (blue). (C) Two
days after infection with HCVbp, Huh-7.5 cells were incubated with BrUTP and NS5A antibody. Huh-7.5 cells with an established HCV subgenomic
replicon were used as a positive control.
doi:10.1371/journal.ppat.1001333.g004
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cholesterol metabolism and lipid droplet formation), are playing a
major role in the permissiveness of BHK-WNV cells. However,
the down or up regulation of other cellular factors could be
involved as well. Thus, several intracellular mechanisms involved
in innate immunity interfere with flavivirus propagation [e.g. 57–
59], and knockdown of interferon stimulating mechanisms or
signaling pathways enhance WNV [58,59] and HCV [60]
productions in cell culture; WNV [61] and HCV [62] proteins
have been shown to directly target such pathways. Here we cannot
exclude that such a mechanism took place prior to or upon
expression of HCV genes. However, the introduction of a BHK
cell-adapted WNV subgenomic replicon into naı ¨ve BHK-21 cells
rendered them rapidly permissive for the production of WNV,
whereas that of HCV appeared after many more passages (not
shown). One possible interpretation is that co-evolution of WNV
subgenomic replicon and BHK cells under antibiotic selection led
to the regulation of additional cellular factors, probably involved in
fine tuning WNV replication and/or translation, but absolutely
required for the production of infectious HCV. This prompted us
to identify such cellular factors in BHK-WNV cells and test their
relevance with the JFH-1 strain/Huh-7.5 cells paradigm, the
results of which will be presented elsewhere.
The entry assay with particles produced in BHK-WNV cells
(HCVrp) requires only the delivery of the associated RNA
molecule into the cytoplasm of the target cell where it can be
translated at sufficient levels to trigger the dual bacteriophage
RNA polymerase amplification system. Thus, the target cell needs
to be permissive only for viral entry, and possibly a limited number
of post-entry steps (e.g. RNA uncoating). Most importantly, the
non-involvement of RNA replication for the signal readout allows
assessment of the entry permissiveness of diverse cell types,
independent of their ability to support HCV replication. This
represents a significant advantage over the HCVcc system that
also relies on viral spreading to amplify the read out signal, and the
involvement of only HCV structural proteins and RNA clearly
distinguishes this system from HCVpp, which is based on non-
HCV protein and nucleic acid platform.
We had previously observed that both ASGP-R subunits were
required for internalization of HCV materials into hepatocellular
carcinoma as well as non-target cells [43]. Here we show that these
subunits are involved in delivering HCV reporter RNA into HCV-
permissive hepatic cells. It is not yet known whether the role of
ASGP-R in HCV uptake relates to incomplete maturation of E1
and/or E2 carbohydrate residues, as previously observed [63,64],
or involves another mechanism [65,66]. HCV has been reported
to enter cultured cells via clathrin-coated pits [67–69], and ASGP-
R internalization follows the same path [66,70]. Yet, ASGP-R can
be targeted to various intracellular compartments including ER
[43], which leaves open the possibility that this receptor plays a
role at an early as well as a late step of the HCV entry process and
RNA delivery.
As inter-genotypic differences and cell-adaptive mutations could
affect viral production in hepatic cells, the BHK-WNV paradigm
provides an alternative model to produce wild type virus for in vivo
or ex vivo studies without the concern that adaptive mutations
develop. It could also present major advantages for deciphering
mechanisms of viral translation, assembly, release and entry,
including involvement of non-structural genes in viral production
independent of their role in replication.
Materials and Methods
Cell cultures
BHK-21 cells were grown in E-MEM supplemented with 10%
fetal bovine serum (FBS; HyClone), GlutaMax-I (Invitrogen);
BHK cells harboring WNV lineage II SG-replicon encoding
Renilla luciferase, BHK WNIIrep-REN cells [32], herein simply
called BHK-WNV cells, were propagated in D-MEM supple-
mented with 10% FBS, GlutaMax-I and 5 mg/ml blasticidin
(Invitrogen). Huh-7.5 cells and Huh-7.5 cells harboring HCV SG-
replicon of 1a genotype (H77) with mutations in NS3 and NS5A
(Huh-7.5-SG 1a rep) were maintained as described [9,10]. HepG2
cells were grown in E-MEM supplemented with 10% FBS,
GlutaMax-I and non-essential amino acid mix. Cells were cultured
in an incubator with a 95% air/5% CO2 atmosphere saturated in
humidity.
Plasmid constructs
A new system of plasmids (p2B) was designed to amplify the
cytoplasmic transcription of plasmids in which the gene of interest
is under the control of a DNA-dependent RNA polymerase
(DdRp)’s cognate promoter; this system consists of a set of two
plasmids generating T7 polymerase (T7 Pol): 1) pCR-T7p/
SP6pol in which bacteriophage SP6 DdRp (SP6pol) gene was
cloned into pCR2.1 plasmid (Invitrogen) in frame with the second
ATG start codon of EMCV IRES under the control of T7
promoter; 2) pSL-SP6p/T7pol in which bacteriophage T7
DdRp (T7pol) gene was cloned into pSL1180 plasmid (Clontech) in
frame with the second ATG start codon of EMCV IRES under
the control of SP6 promoter. This p2B system was used for all T7
Pol promoter-driven HCV coding plasmids, in which a sequence
coding for an HDV antigenomic ribozyme [71] was added at their
C termini. p90 HCVconFLlongpU encoding the FL genome of
infectious H77 strain [46], or, pH-Neo-SG(L+I) encoding a
subgenomic replicon of the same strain with cell-culture adaptive
mutations [9] were used as templates to construct all HCV coding
plasmids of genotype 1a. HCVbp was produced from p684-
SG(L+I)-HDV plasmid, in which the neomycin resistance gene of
pH-Neo-SG(L+I)-HDV, i.e. pH-Neo-SG(L+I) encoding an
hepatitis delta virus antisense ribozyme (HDV rbz) after the
HCV 39-end, was replaced with HCV 59-UTR to NS2 coding
sequence. An HDVrbz gene was introduced at the 39-end of
p90HCVconFLlongpU to create p90-T7p/H77FL-HDV plas-
mid that will produce HCVwt, i.e. virus particles containing the
full-length, consensus sequence of H77 strain. HCVbp-4cys and
HCVwt-4cys were obtained using modified p684-SG(L+I)-HDV
and p90-T7p/H77FL-HDV plasmids, in which a tetracysteine
Figure 5. Study of entry of BHK-WNV cell-produced HCV particles. (A) Parental HepG2 and HepG2-CD81 cells were incubated with HCVbp
and NS5A expression was analyzed two days later by laser scanning confocal microscopy. (B) pCMV(-)T7p/HCV SP6pol-HDV plasmid was used to
produce HCVrp that encapsidate a bicistronic reporter RNA encoding HCV core to NS2 and SP6 Pol, and ending with HCV NS5B C-terminus to 39-UTR
RNA (=kissing loops). To detect incoming-SP6pol RNA following HCVrp entry, target cells were transfected with a reporter plasmid (pT7-SP6p2/
EGFPLuc); its co-transfection with the p2B system enhanced the cytoplasmic transcription of the reporter plasmid triggered by incoming SP6pol RNA
in target cells; a treatment with actinomycin D decreased the background signal. (C) HCVrp and WNVrp were incubated with siRNA-treated Huh-7.5
cells, as indicated. HCV (filled bars) or WNV (open bars) incoming signals into target cells were measured using Firefly or Renilla luciferase assay,
respectively. Error bars represent the SD of triplicate experimental points; these results are representative of n=5 independent experiments.
doi:10.1371/journal.ppat.1001333.g005
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gene. HCVrp was produced from pCMV(-)T7p/HCV-SP6pol-
HDV plasmid that encodes HCV 59-UTR and structural genes
followed by those of SP6pol (entry signal) gene in frame with
EMCV IRES and a sequence encoding carboxy-terminus of HCV
NS5B (kissing loops) [73] and 39-UTR. To detect incoming-
SP6pol RNA upon HCVrp entry into target cells, pT7-SP6p2/
EGFPLuc reporter plasmid was made. This plasmid was derived
from pEGFPLuc plasmid (Clontech) in which EMCV-IRES-
EGFPLuc expression is under the control of both bacteriophage
T7 Pol and SP6 Pol cognate promoters in tandem. This construct
lacks eukaryotic promoter and therefore is responsive either to T7
Pol, SP6 Pol, or both; it was found responding to either incoming
DdRp, be it in the form of protein or DdRp encoding RNA (not
shown). Two additional constructs, pHCVp7 and pHCVcore-NS2
are pcDNA3.1(+)-based plasmids (Invitrogen), respectively encod-
ing HCV 1a structural genes (core, E1, E2, p7) and HCV 1a
structural genes plus NS2. pIRES1hyg-WNV [32] encodes WNV
structural genes (core, prM and E). These three plasmids are under
CMV early promoter (not shown). pJFH1 [11], pFK1-Con1
(9605Con1) [7] and pFK-JFH1Con1C-842 [18] are plasmids
encoding from a T7 Pol promoter the genomic RNA of,
respectively, the JFH-1 strain (genotype 2a), the Con1 strain
(genotype 1b) and a Con1-JFH1 chimera (1b/2a). A DNA
fragment encoding an HDV rbz was inserted at the 39-end of
the HCV RNA coding region of each plasmid.
Antibodies and live-cell staining
Anti-E2 monoclonal antibodies (ALP98 and AP33) [74] and
anti-E1 (A4) monoclonal antibody were used for Western blot
analysis, and rabbit polyclonal antibody against HVR1 of E2 [45]
for inhibition of HCVrp entry. Anti-NS5A rabbit polyclonal
antibody (in-house) was used for confocal microscopy analysis. To
produce rabbit antibody against NS5A of genotype 1a, 48-amino-
acid peptide: NH2-AEEDEREVSVPAEILRKSRRFARALPV-
WARPDYNPPLVETWKKPDYEP-COOH, corresponding to
position 2261–2308 of the H77 strain was synthesized by Peptide
Synthesis and Analysis Laboratory (RTB/NIAID/NIH); a cyste-
ine residue was introduced at the amino-terminus and the peptide
was coupled to KLH. Two rabbits were immunized from which
two sera were harvested; both IgGs were peptide affinity-purified.
Sequence of the peptide is almost identical (but amino acids 22,
25, 43 and 46) to that of Con1 (genotype 1b). Monoclonal
antibody against HCV core protein (clone C7-50; Thermo
Scientific) was used to analyze Huh-7.5-produced JFH-1 (HCVcc)
infection by confocal microscopy. Antibodies against HCV
candidate receptors and cellular proteins are as follow: anti-
CD81 mAb (JS-81, BD Biosciences); anti-SR-BI rabbit polyclonal
antibody (Novus Biologicals); anti-ASGPR-1 mAb (clone 8D7,
Santa Cruz Biotechnology); anti-claudin mAb (Invitrogen); anti-
Hsp70 (BD Biosciences); anti-ERGIC-53 (Alexis Biochemicals)
and anti-BrdU (Invitrogen). FIAsH- and ReAsH-EDT2 labeling
reagents were obtained from Molecular Probes (Invitrogen). For
flow cytometry and immunofluorescence (confocal microscopy)
analysis, the secondary antibodies used were Alexa Fluor 488-,
594-, or 635-conjugated goat anti-mouse and anti-human
antibodies, and Alexa Fluor 594-, 635-, or 680-conjugated goat
anti-rabbit antibodies from Molecular Probes (Invitrogen).
Production of HCV particles
One day before transfection, BHK-WNV cells were seeded at a
density of 6610
6 cells per 162-cm
2 flask. Plasmids encoding HCV
sequence under the control of bacteriophage T7 promoter (or
CMV early promoter where specified) were transfected using
Lipofectamine LTX and Plus reagent according to the manu-
facturer’s protocol (Invitrogen). Culture medium after transfec-
tion was D-MEM supplemented with 10% FBS, 1% non-essential
amino acid mix, GlutaMax-I, 25 mM Hepes; cells were
incubated at 37uC. One or two days later, 2.5 to 3.7 g/L sodium
bicarbonate was added (to prevent further acidification of the
medium), and culture medium were harvested at day 3,
centrifuged at 30,0006 g for 30 min at 4uC to remove cell
debris, then clarified supernatants were centrifuged at 100,0006g
for 3 hrs at 4uC. Pellets were either resuspended in culture
medium and filtered through 0.45 mm PVDF membrane
(Millipore), or loaded on the top of a 20–60% sucrose gradient
in phosphate-buffered saline solution (PBS; Quality Biologicals,
MD), then centrifuged in a SW55Ti rotor (Beckman) at
100,0006g for 16 hrs at 4uC. Gradients were manually harvested
from the top in 150 ml fractions. HCVcc (Huh-7.5-produced
JFH-1) was obtained by electroporating IVT RNA into Huh-7.5
cells as described [11]. Virus stock was concentrated, aliquoted
and stored at 280uC.
Electron microscopy
BHK-WNV cells (2.5610
5) seeded in a 6-well plate were
transfected with HCVbp-coding plasmid. Three days later, cells
were fixed in 2% glutaraldehyde in 0.1 M sodium cacodylate for
1 hr at RT, then at 4uC, overnight. Cells were subsequently
processed for TEM as described [75]. Pooled sucrose fractions
containing HCVwt were diluted with PBS then pelleted in
Beckman SW55Ti (100,0006 g, for 2 hr) at 4uC. Pellets were
resuspended in 4% paraformaldehyde in PBS and analyzed for
negative staining EM. Serum from a cured HCV patient
previously infected with genotype 1a was used to detect HCVwt
in the immuno-EM analysis.
Infectivity assay with HCVbp or HCVwt
Virus-containing supernatant from BHK-WNV cells were
clarified at 30,0006 g in SW28 Beckman rotor for 30 min,
filtered through 0.45 mm PVDF membranes then concentrated
(60-fold) with 10
6 MWCO Vivaspin filters (Sartorius Stedim,
Gottingen, Germany). Huh-7.5 cells (7610
3) were seeded in a 8-
well chamber coverglass (Lab-Tek II, Nalge Nunc) and incubated
with HCVbp for 2 hr at 37uC. After virus inoculum removal,
cells were grown for another 48 hr to analyze the expression of
HCV NS5A protein. Briefly, cells were washed twice with ice-
cold PBS and fixed with 4% paraformaldehyde and 0.15 M
sodium cacodylate buffer, pH 7.4, for 20 min at room temper-
Figure 6. JFH-1-based HCV produced in BHK-WNV cells infect Huh-7.5 cells. Huh-7.5 cells were seeded one day before the experiment and
treated with (open symbols, dashed lines) or without (closed symbols) leukocyte interferon (100 IU/ml) plus ribavirin (400 mM). JFH-1 (A) and Con1-
JFH1 (B) HCV particles produced in BHK-WNV cells were incubated with the Huh-7.5 cells for 2 hrs; after several washes, the cells were split and an
equivalent amount of cells were either directly harvested (day 0) or seeded onto collagen-I-coated 24-well plates (and interferon plus ribavirin
treatment was re-introduced where applies) and further cultured for the indicated times. Cells were then harvested and HCV 59-UTR RNA was subject
to RT-qPCR analysis, as in (Fig. 4A). Errors bars represent SD of 4 measurements; the limit of detection in this assay is indicated by a dotted line;
nd=undetermined values (i.e. ,10
5 HCV RNA copies/well).
doi:10.1371/journal.ppat.1001333.g006
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containing 50 mM glycine. After washing with PBS, cells were
permeabilized with 0.3% Triton X-100 in PBS for 15 minutes at
room temperature, then incubated with blocking solution (10%
FBS, 3% BSA, 0.3% Triton X-100 in PBS) for 30 min. Cells
were then incubated with primary antibodies: rabbit anti-NS5A
IgG and anti-ERGIC-53 mAb (in 1% BSA, 0.1% Triton X-100,
in PBS) overnight at 4uC. The fluorescent secondary antibodies
were Alexa Fluor 488-conjugated anti-mouse IgG antibody and
Alexa Fluor 594- or 635-conjugated anti-rabbit IgG antibodies.
Nuclei were labeled with DAPI with antifade (Chemicon, CA).
To test the infectivity of HCVwt (1a, 1b and 2a) produced by
BHK-WNV cells, HepG2-CD81 cells were seeded on 24-well
collagen plates, and the following day, cells were incubated with
particles in the presence or absence of IFN-a and ribavirin. Total
RNA was harvested daily and intracellular HCV RNA was
measured by RT-Taqman PCR.
Live-cell imaging
Cells were infected with HCV particles containing a genome
encoding a tetracysteine-tag (HCVbp-4cys or HCVwt-4cys): Huh-
7.5 cells were infected with HCVbp-4cys for 3 days, then
incubated with the cell-permeant FIAsH-EDT2 or ReAsH-EDT2
biarsenical dye according to the manufacturer’s protocol (Molec-
ular Probes, Invitrogen). Adding FIAsH (or ReAsH) dye onto live
cells expressing TC-tagged proteins should result in a specific
fluorescent signal where the tag is present. Samples were observed
under a confocal microscope (SP5 X-WLL (white light laser)
mono-photon confocal microscope (Leica, Heidelberg, Germany)
using a 636 oil immersion objective NA 1.32. Images were
deconvolved with Huygens Essential software (Version 5.3,
Scientific Volume Imaging BV, Hilversum, The Netherlands). A
similar procedure was used to stain cultured human liver slices
infected with HCVwt-4cys.
Bromo-uridine incorporation in Huh-7.5 cells
Huh-7.5 cells (7610
3) were seeded in 8-well chamber coverglass
and one day later, were infected with HCVbp. At 48 hr post-
infection, medium was replaced with D-MEM complete medium
containing 2.5 mg/ml actinomycin D (Sigma) for 30 min and
transfected with 5-bromo-uridine 59-triphosphate (BrUTP; Sigma)
using Lipofectamine 2000 (Invitrogen). Briefly, 1 ml of Lipofecta-
mine 2000 was added to 10 mM BrUTP, both in 25 ml Opti-
MEM I, and incubated for 20 min at room temperature. The
BrUTP-Lipofectamine complex was added drop wise onto cells
and further incubated for 6 hours. Cells were then fixed,
permeabilized and incubated with Alexa Fluor 488 conjugated-
anti-BrdU mAb. Confocal microscopy analysis was performed as
above.
RNA analysis and RT-qPCR
Total RNA from sucrose fractions was extracted with Trizol LS
(Invitrogen) and RT-TaqMan PCR of HCV 59-UTR RNA was
performed with QuantiTect Probe PCR kit (Qiagen) using IVT
RNA standard corresponds to the HCV 59-UTR. HCV RNA was
analyzed directly from infected cells harvested daily using lysis
buffer of TaqMan Gene Expression Cells-to-CT kit (Ambion,
Applied Biosystems, Invitrogen); RNA was subjected to a RT step
followed by HCV TaqMan qPCR analysis performed with HCV
specific primers, and HCV 59-UTR/NH2-core in vitro transcripts
as RT-PCR standards. For HCV and WNV RNA analysis from
BHK-WNV cells: Total RNA was extracted from cells and
pelleted supernatants with Trizol LS followed by RT using
random hexamer and Superscript III at 50uC, for 1 hr. Renilla
luciferase-specific primers as the target gene for WNV-SG rep
RNA. See Text S1 for details.
Determination of HCVbp (or HCVcc) TCID50
The released particles were filtered, concentrated and serially
diluted before incubated with Huh-7.5 cells for 3–4 days. NS5A-
positive cells were analyzed by immunofluorescence and the
number of positive cells was determined using Odyssey In-cell
Western system (Li-Cor Biosciences, Lincoln, NE). See Text S1 for
details.
Transduction of HepG2 cells with hCD81-lentivirus
The cDNA of human CD81 (hCD81) from Huh-7.5 cells were
amplified by reverse transcription (RT)-PCR and cloned into
pENTR 2B (Invitrogen) followed by recombination with
pLenti6.2/V5-DEST (Invitrogen) to according to manufacturer’s
recommendation. See Text S1 for details.
Infection of cultured human liver slices
Human liver slices were infected with HCVcc (JFH-1)
produced in Huh-7.5 cells, HCVwt produced in BHK-WNV
cells, or not infected. Six-to eight days after infection, co-
immunostaining was performed with HCV serum or monoclonal
antibodies, followed by DyLight 488 conjugated-anti-human IgG
F(ab9)2 (Jackson ImmunoResearch Laboratories, West Grove,
PA), or Alexa Fluor 546 conjugated-anti-mouse IgG goat
antibody (Invitrogen). Liver slices were analyzed with a mono-
photon multi-focal confocal microscope (Leica SP5 Resonant
Scanner, Heidelberg, Germany) coupled to a high resolution
CCD. For live-cell staining, human liver slices were infected with
HCVwt-4cys (HCVwt encoding a tetracysteine tag) for 6 days,
incubated with the cell-permeant TC-FIAsH dye and analyzed
(over a thickness of 100–150 mm) as above, using a multi-photon
mono-focal confocal microscope (Leica TCS SP5 Resonant
Scanner, Heidelberg, Germany).
HCVrp entry assay with the reporter system and
production of WNV reporter particles
See Text S1 for details.
Huh-7.5 cell gene knockdown using siRNAs
See Text S1 for details.
Figure 7. Wild-type HCV produced in BHK-WNV cells infect human liver slices. (A) Transfection of p90-T7p/H77FL-HDV in BHK-WNV cells
yielded authentic HCV particles (HCVwt) that encapsidate a full-length, wild-type genome of H77 strain. (B) HCVwt particles released by BHK-WNV
cells were analyzed by ultracentrifugation on a sucrose gradient; fractions with buoyant densities of 1.08–1.13 g/cm
3 were pooled and observed by
negative staining (EM) or immuno-gold electron microscopy (IEM, using serum from HCV-cured patient). (C) (Upper panels) Human liver slices were
uninfected (left), or infected with BHK-WNV-produced HCVwt (H77, center), or HCVcc produced in Huh-7.5 cells (JFH-1, right), then cultured for 8
days. Co-incubation with anti-HCV antibodies (cf. Materials and Methods) resulted in specific staining observed over a thickness of 60–70 mm with a
multifocal confocal microscope. (Lower panels) Human liver slices were infected with BHK-WNV-derived HCVwt-4cys for 6 days, then stained with
FIAsH and observed over a thickness of ,150 mm with a multiphoton confocal microscope; ML=mediolobular area; PP=periportal space; white
arrows indicate positive cells.
doi:10.1371/journal.ppat.1001333.g007
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Figure S1 Inhibition of HCV structural proteins release by
HCV and SFV subgenomic replicons in Huh-7.5 and BHK-21
cells, respectively.
Found at: doi:10.1371/journal.ppat.1001333.s001 (0.69 MB PPT)
Figure S2 Immuno-EM of BHK-WNV cells transfected with
HCVbp-coding plasmid.
Found at: doi:10.1371/journal.ppat.1001333.s002 (3.70 MB PPT)
Figure S3 A. Detection of HCV core, E1, E2 of HCVbp after
fractionation on a 20–60% sucrose gradient. B. Effect of brefeldin A on
HCV release. C. HCV release required maturation of viral
glycoproteins. D. WNV, but not HCV, structural proteins trans-
encapsidate WNV SG-replicon that is infectious in Huh-7.5 cells. E.
Effect of antiviral treatment of WNV SG-replicon on HCV release by
BHK-WNV cells.
Found at: doi:10.1371/journal.ppat.1001333.s003 (4.56 MB PPT)
Figure S4 A. Co-localization of 4cys-HCVbp with lipid droplets
in BHK-WNV cells. B. Pre-incubation of HCVbp with serum
from HCV-cured patient abolished its infectivity. C. Specificity of
in-house HCV NS5A rabbit polyclonal antibody. D. Infection of
Huh-7.5 cells with HCVbp-4cys.
Found at: doi:10.1371/journal.ppat.1001333.s004 (1.12 MB PPT)
Figure S5 A. Surface expression of human CD81 by HepG2-
CD81 cells. B. BHK-WNV cells, but not parental BHK-21,
produced infectious HCVrp. C. HCV receptors knockdown by
siRNA in Huh-7.5 cells. D. Inhibition of HCVrp entry by anti-
CD81 and anti-SR-BI antibodies. E. Inhibition of HCVrp entry
by anti-HVR-1 antibodies. F. Effect of NS2 on the buoyant
densities and infectivity of HCVrp.
Found at: doi:10.1371/journal.ppat.1001333.s005 (0.70 MB PPT)
Figure S6 Control liver slices with secondary antibodies.
Found at: doi:10.1371/journal.ppat.1001333.s006 (3.18 MB PPT)
Table S1 Correlation between HCVrp infectivity and candidate
receptor expression in several cell lines.
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